JP2005520834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005520834A5 JP2005520834A5 JP2003576974A JP2003576974A JP2005520834A5 JP 2005520834 A5 JP2005520834 A5 JP 2005520834A5 JP 2003576974 A JP2003576974 A JP 2003576974A JP 2003576974 A JP2003576974 A JP 2003576974A JP 2005520834 A5 JP2005520834 A5 JP 2005520834A5
- Authority
- JP
- Japan
- Prior art keywords
- cxcr4
- lung cancer
- inhibitor
- small cell
- receptor tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 59
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 58
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 32
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 28
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 27
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 27
- 239000003112 inhibitor Substances 0.000 claims description 19
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 11
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 230000004660 morphological change Effects 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 230000021164 cell adhesion Effects 0.000 claims description 3
- 230000012292 cell migration Effects 0.000 claims description 3
- 230000009087 cell motility Effects 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 229940124204 C-kit inhibitor Drugs 0.000 claims 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 4
- 210000005265 lung cell Anatomy 0.000 claims 2
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 230000000692 anti-sense effect Effects 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091033380 Coding strand Proteins 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 102000053523 human CXCR4 Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36637002P | 2002-03-20 | 2002-03-20 | |
| PCT/EP2003/002916 WO2003079020A2 (en) | 2002-03-20 | 2003-03-20 | Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005520834A JP2005520834A (ja) | 2005-07-14 |
| JP2005520834A5 true JP2005520834A5 (https=) | 2006-05-18 |
Family
ID=28042053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003576974A Pending JP2005520834A (ja) | 2002-03-20 | 2003-03-20 | 小細胞肺癌の同定、診断、および治療のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050233991A1 (https=) |
| EP (1) | EP1488239A2 (https=) |
| JP (1) | JP2005520834A (https=) |
| AU (1) | AU2003226676A1 (https=) |
| WO (1) | WO2003079020A2 (https=) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
| PT1942108E (pt) | 2005-10-28 | 2013-10-24 | Ono Pharmaceutical Co | Composto com um grupo básico e a sua utilização |
| CN101316590B (zh) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| US12366585B2 (en) | 2006-05-18 | 2025-07-22 | Caris Mpi, Inc. | Molecular profiling of tumors |
| IL313131A (en) * | 2009-02-11 | 2024-07-01 | Caris Mpi Inc | Molecular characterization of tumors |
| DK2468281T3 (en) | 2009-08-19 | 2016-03-21 | Eisai R&D Man Co Ltd | Quinolinderivatholdig pharmaceutical composition |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| EP2997377B1 (en) | 2013-05-14 | 2018-07-18 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| WO2015164772A1 (en) * | 2014-04-25 | 2015-10-29 | Rush University Medical Center | Circulating insulin-like growth factor (igf)-associated proteins for the detection of lung cancer |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3568160A1 (en) * | 2017-01-16 | 2019-11-20 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Improved multi tyrosine kinase inhibitor therapy |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| EP3624800A4 (en) | 2017-05-16 | 2021-02-17 | Eisai R&D Management Co., Ltd. | TREATMENT OF HEPATOCELLULAR CARCINOMA |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US107195A (en) * | 1870-09-06 | Improvement in sawing-machine | ||
| AU4471297A (en) * | 1996-10-07 | 1998-05-05 | Kyowa Hakko Kogyo Co. Ltd. | Fused purine derivatives |
| WO2000009152A1 (en) * | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| US20020107196A1 (en) * | 1998-07-21 | 2002-08-08 | Smithkline Beecham Corporation | Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha |
| AU4692400A (en) * | 1999-05-03 | 2000-11-17 | Smithkline Beecham Corporation | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| JP2003512856A (ja) * | 1999-11-04 | 2003-04-08 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ウテログロビン様ポリヌクレオチド、ポリペプチド、および抗体 |
-
2003
- 2003-03-20 US US10/507,549 patent/US20050233991A1/en not_active Abandoned
- 2003-03-20 JP JP2003576974A patent/JP2005520834A/ja active Pending
- 2003-03-20 AU AU2003226676A patent/AU2003226676A1/en not_active Abandoned
- 2003-03-20 WO PCT/EP2003/002916 patent/WO2003079020A2/en not_active Ceased
- 2003-03-20 EP EP03744382A patent/EP1488239A2/en not_active Withdrawn
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
| US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005520834A5 (https=) | ||
| AU743490B2 (en) | NTN-2 member of TNF ligand family | |
| JP3415162B2 (ja) | Ｉｌ―１３受容体ポリペプチド | |
| CA2690399C (en) | Il-6 antagonist peptides | |
| JP2002053490A (ja) | マクロファージ炎症蛋白質−３、−４および−１γ | |
| CN1143372A (zh) | 血细胞生成成熟因子 | |
| KR20060023968A (ko) | 중증 급성 호흡기 증후군(ｓａｒｓ)의 치료를 위한 조성물및 방법 | |
| JP2003047492A (ja) | ヒトケモカインベータ−９ | |
| US6338949B1 (en) | Nucleic acids encoding receptor recognition factor stat4 and methods of use thereof | |
| CN1668630A (zh) | 新的血管内皮细胞生长抑制剂同种型 | |
| JP3908165B2 (ja) | 多発性硬化症の治療におけるケモカイン変異体 | |
| JP3373856B2 (ja) | Ｇｐ１３０に全く結合することができないヒトインターロイキン−６の拮抗薬、および医薬化合物の製造におけるそれらの使用 | |
| CA3180251A1 (en) | Cytokine conjugates | |
| CA2922127C (en) | Combination of cytokine and cytokine receptor for altering immune system functioning | |
| JP2005525089A (ja) | ケモカイン・アンタゴニストとして作用するケモカイン突然変異体 | |
| AU711573B2 (en) | Short forms of chemokine beta-8 | |
| JP3907661B2 (ja) | インターフェロン−α／β結合タンパク質、その製造法およびそれを含有する医薬組成物 | |
| Neville et al. | Mob-1 expression in IL-2-induced ARDS: regulation by TNF-alpha | |
| WO2022056493A1 (en) | Biomarker driven methods for treating major depressive disorder | |
| JP2000125888A (ja) | シアロアドヘシンファミリ―メンバ――３ | |
| WO2001038522A1 (fr) | Nouveau polypeptide, histone humaine h2a.21, et polynucleotide codant pour ce polypeptide | |
| US6605442B1 (en) | Methods of testing drugs or agents that modulate the activity of receptor recognition factors | |
| US20030073162A1 (en) | Signal peptide-containing proteins | |
| AU734252B2 (en) | Novel mouse CXC chemokine receptor | |
| AU764484B2 (en) | Orphan cytokine receptor |